UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-41462 SBC Medical Group Holdings Incorporated (Exact Name of Registrant as Specified in Its Charter) | Delaware | 88 ...

Table of Contents FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-37950 KARTOON STUDIOS, INC. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES (Exact name of registrant as specified in its charter) (State or other ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-37950 KARTOON STUDIOS, INC. (Exact name of registrant as specified in its charter) (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to ________. Commission File Number 001-41723 BRANCHOUT FOOD INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (Exact name of registrant as specified in charter) | Israel | | --- | | Not applicable | (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (Exact name of registrant as specified in charter) | Israel | | --- | | Not applicable | (State or other jurisdiction ...

Revenue Growth - Security segment revenues increased by $8,896,220 or 110% to $16,981,152 for the three months ended March 31, 2025, driven by a large sale of $10,375,000, representing 61% of the segment's revenue [135] - Industrial Services segment revenues increased by $1,194,454 or 13% to $10,269,117 for the three months ended March 31, 2025, due to increased demand for services [136] - Security segment revenues for the six months ended March 31, 2025, increased by $5,182,118 or 30% to $22,434,851, with a large sale of $10,375,000 representing 46% of the segment's revenue [144] Profitability - Gross profit for the three months ended March 31, 2025, was $12,165,455 or 45% of revenues, up from $6,969,416 or 40% for the same period in 2024 [137] - Gross profit for the six months ended March 31, 2025, was $17,867,391 or 44% of revenues, compared to $14,021,815 or 41% for the same period in 2024 [146] - Other income for the three months ended March 31, 2025, was $4,104,211, primarily driven by gains on changes in fair value of warrant liability of $4,707,374 [142] Expenses Management - Research and Development expenses decreased by $173,511 or 18% to $777,889 for the three months ended March 31, 2025, related to the development of next-generation security solutions [141] - General and administrative expenses decreased by $128,092 or 1% to $13,864,031 for the six months ended March 31, 2025, due to reduced salaries and operating expenses [149] Cash Flow and Liquidity - Cash provided by operating activities for the six months ended March 31, 2025, was $1,600,532, contrasting with a cash usage of $2,752,236 for the same period in 2024 [155] - Trade receivables increased by $1,556,316 or 14% to $12,715,992 at March 31, 2025, attributed to the remaining balance on the large sale in the Security segment [156] - The company currently lacks adequate cash or available liquidity to meet short or long-term needs [160] - There is uncertainty regarding the sufficiency of cash flow from existing or future operations to meet working capital needs [160] - The unaudited condensed consolidated financial statements do not include adjustments related to the company's financial uncertainty [162] Strategic Objectives - The company aims to increase marketing and sales across all segments and expand presence through collaborations and strategic acquisitions [161] - Long-term growth objectives will require sufficient cash, which may be funded through cash on hand, debt issuance, and proceeds from securities sales [161] - The company may face a dilutive effect on existing stockholders if additional capital is raised through equity offerings or debt satisfied with equity [160]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________ Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-36426 ____________ AquaBounty Technologies, Inc. (Exact name of registrant as spe ...

Revenue and Income - Total revenues for Q1 2025 were $47 million, a 14% year-over-year decrease due to the discontinuation of the staffing business and divestitures [4]. - Total revenues for the three months ended March 31, 2025, were $47,328,701, a decrease of 13.7% compared to $54,808,042 for the same period in 2024 [17]. - Net income attributable to SBC Medical Group increased by 15% year-over-year to $22 million, compared to $19 million in Q1 2024 [6]. - Net income attributable to SBC Medical Group Holdings Incorporated for Q1 2025 was $21,502,446, representing an increase of 14.7% from $18,757,752 in Q1 2024 [17]. EBITDA and Margins - EBITDA for Q1 2025 was $25 million, representing a 3% year-over-year decrease, with an EBITDA margin of 52%, up from 46% in Q1 2024 [4]. - EBITDA for the three months ended March 31, 2025, was $24,830,378, with an EBITDA margin of 52%, compared to an EBITDA of $25,479,362 and a margin of 46% in Q1 2024 [23]. - Operating margin improved from 45% in Q1 2024 to 51% in Q1 2025, showcasing enhanced profitability [3]. Customer Metrics - The total number of customers in the last twelve months ended March 31, 2025, was 6.1 million, reflecting a 14% year-over-year increase [4]. - The repeat customer rate for franchise clinics was 71%, indicating strong customer loyalty [4]. - The number of partner clinics increased to 251 as of March 31, 2025, an increase of 36 clinics from the previous year [4]. Cash and Assets - Cash and cash equivalents as of March 31, 2025, were $132.06 million, an increase from $125.04 million at the end of 2024 [12]. - Cash and cash equivalents at the end of the period increased to $132,055,823, up from $96,181,550 at the end of Q1 2024 [21]. - Total assets increased to $284.61 million as of March 31, 2025, compared to $266.08 million at the end of 2024 [15]. Operating Expenses and Other Income - Operating expenses decreased to $13,531,010 in Q1 2025 from $15,058,490 in Q1 2024, reflecting a reduction of 10.1% [17]. - The company reported a gain on redemption of life insurance policies amounting to $8,746,138 in Q1 2025 [17]. - Interest income increased to $55,333 in Q1 2025, compared to $17,689 in Q1 2024, marking a growth of 212.5% [17]. - The net cash provided by operating activities for Q1 2025 was $1,928,621, down from $3,682,175 in Q1 2024 [21]. - The company experienced a foreign currency translation adjustment resulting in other comprehensive income of $9,808,327 in Q1 2025, compared to a loss of $10,193,852 in Q1 2024 [17]. Share Information - The weighted average shares outstanding for basic and diluted earnings per share increased to 103,276,637 in Q1 2025 from 94,192,433 in Q1 2024 [17]. Strategic Focus - The company is focusing on strategic expansion and optimizing its profitability structure to adapt to changing market dynamics [3].

Financial Performance - Total revenues for the first quarter of 2025 were $47 million, reflecting a 14% year-over-year decrease due to the discontinuation of the staffing business and divestitures[4] - Net income attributable to SBC Medical Group increased by 15% year-over-year to $22 million, compared to $19 million in the same period of 2024[6] - EBITDA for the first quarter of 2025 was $25 million, representing a 3% year-over-year decrease, with an EBITDA margin of 52%, up from 46% in the first quarter of 2024[4] - Total revenues for the three months ended March 31, 2025, were $47,328,701, a decrease of 13.7% compared to $54,808,042 for the same period in 2024[17] - Net income attributable to SBC Medical Group Holdings Incorporated increased to $21,502,446, up 14.7% from $18,757,752 in the prior year[17] - EBITDA for the three months ended March 31, 2025, was $24,830,378, with an EBITDA margin of 52%, compared to an EBITDA of $25,479,362 and a margin of 46% in 2024[23] - Operating expenses decreased to $13,531,010, down 10.1% from $15,058,490 in the previous year[17] - The company reported a gain on redemption of life insurance policies amounting to $8,746,138, which was not present in the prior year[17] - Interest income rose to $55,333, compared to $17,689 in the same period last year, reflecting a significant increase[17] - The company reported a total other income of $7,249,333, significantly higher than $2,741,315 in the same period last year[17] Customer Metrics - The number of partner clinics increased to 251 as of March 31, 2025, an increase of 36 clinics from the previous year[4] - The total number of customers in the last twelve months ended March 31, 2025, was 6.1 million, marking a 14% year-over-year increase[4] - The repeat rate for customers who visited franchisee clinics twice or more was 71%[4] Profitability and Margins - Operating margin improved from 45% in the first quarter of 2024 to 51% in the first quarter of 2025[3] - Return on equity was 41%, representing a year-over-year decrease of 10 percentage points[4] Strategic Focus - SBC Medical is focusing on strategic expansion and optimizing profitability through revised pricing strategies and adapting to market dynamics[3] - The company aims to build a scalable franchise model while accelerating expansion across domestic and international markets[3] Cash and Other Financial Adjustments - Cash and cash equivalents at the end of the period increased to $132,055,823, compared to $96,181,550 at the end of the same period in 2024[21] - The company experienced a foreign currency translation adjustment resulting in other comprehensive income of $9,808,327, compared to a loss of $10,193,852 in 2024[17] - Net cash provided by operating activities was $1,928,621, a decrease from $3,682,175 in the prior year[20]